Evidence map›Paper›PMID 33835334›Full record

ReviewJournal of thrombosis and thrombolysis2021

Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension.

Mateo Porres-Aguilar, Marius M Hoeper, Belinda N Rivera-Lebron, Gustavo A Heresi, Debabrata Mukherjee, Victor F Tapson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of thrombosis and thrombolysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Mateo Porres-AguilarDivision of Hospital Medicine, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. mporres1980@gmail.com.ORCID http://orcid.org/0000-0002-2180-3000
Marius M HoeperDepartment of Respiratory Medicine, Hannover Medical School and German Center of Lung Research (DZL), Hannover, Germany.ORCID https://orcid.org/0000-0001-9086-2293
Belinda N Rivera-LebronDivision of Pulmonary and Critical Care Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0002-7842-671X
Gustavo A HeresiDepartment of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID https://orcid.org/0000-0002-9797-2599
Debabrata MukherjeeDivision of Cardiovascular Diseases, Department of Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, TX, USA.ORCID http://orcid.org/0000-0002-5131-3694
Victor F TapsonDivision of Pulmonary and Critical Care Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0001-9708-1457
Texas Tech University · USCedars-Sinai Medical Center · USCleveland Clinic · USMedizinische Hochschule Hannover · DEUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) represents the later stage consequence of at least one or more unresolved episodes of acute pulmonary embolism; thus, indefinite anticoagulation is strongly recommended by current practice guidelines. Historically, vitamin K antagonists have been widely used in these patients. However, recent data indicate a shift toward direct oral anticoagulants (DOACs), despite lack of data on the safety and efficacy in this patient population. Herein, we briefly discuss the current rationale for oral anticoagulation use in CTEPH, addressing important issues and controversies involved with the use of DOACs, opening a strategy for further clinical research in the field of oral anticoagulation.

Indexed as

Hypertension, PulmonaryAdministration, OralAnticoagulantsHumansPulmonary EmbolismVenous ThromboembolismVitamin KAnticoagulantsVitamin KChronic thromboembolic pulmonary hypertensionDirect oral anticoagulantsOral anticoagulationPulmonary embolismVenous thromboembolismVitamin K antagonistsWarfarin

Identifiers

PMID33835334
OpenAlexW3140878722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.